By Rob Wynden, PhD, & Elvin Thalund
Testing the safety and efficacy of new drugs is a costly and complex process for pharmaceutical organizations. The rising cost and complexity compromises profitability and can stifle research and innovation. Adding to that frustration is the fact that technologies companies use for specific phases of a clinical trial, such as clinical trial management (CTMS) and trial master file (TMF) systems, cannot be applied to the other phases. The fact is, there is no single magic pill that can accelerate clinical trials.